Nomura Holdings
SMMT icon

Nomura Holdings’s Summit Therapeutics SMMT Stock Holding History

Nomura Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
18,000
-6,000
-25% -$106K ﹤0.01% 1628
2026
Q1 		$455K Buy
+24,000
New +$388K ﹤0.01% 1393
2025
Q4 		– Sell
-60,000
Closed -$1.24M – 2142
2025
Q3 		$1.24M Buy
+60,000
New +$1.46M ﹤0.01% 1323

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nomura Holdings's SMMT Position: Q2 2026 in Review

Nomura Holdings reduced its Summit Therapeutics (SMMT) stake by 64% in Q2 2026, selling an estimated $3.58M and leaving 112,359 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Nomura Holdings first reported a position in SMMT in Q1 2023 and has held it in 7 quarters since. The position peaked at $21.7M in Q3 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Nomura Holdings held 112,359 shares of Summit Therapeutics worth $1.64M as of Q2 2026.
  • Nomura Holdings sold 201,622 Summit Therapeutics shares in Q2 2026, an estimated $3.58M.
  • Summit Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1184 holding.
  • Nomura Holdings first reported a position in Summit Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • Nomura Holdings's Summit Therapeutics position peaked at $21.7M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.